Global Leading Market Research Publisher QYResearch announces the release of its latest report “Chiral Synthesis Technology Platform – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global chiral synthesis technology platform market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for chiral synthesis technology platform was estimated to be worth US5.2billionin2025andisprojectedtoreachUS5.2billionin2025andisprojectedtoreachUS 9.8 billion, growing at a CAGR of 9.4% from 2026 to 2032. This robust growth is driven by the increasing regulatory requirement for single-enantiomer drugs, the expiration of key chiral blockbuster patents (e.g., apixaban, levetiracetam), and the rising adoption of biocatalysis as a greener alternative to traditional metal-based asymmetric synthesis.
Chiral synthesis technology platform refers to a set of methodologies, techniques, and tools that enable the efficient production of chiral molecules. Chiral molecules are those that possess a non-superimposable mirror image, known as enantiomers. Enantiomers can exhibit different chemical, biological, and pharmacological properties, making their separation and production essential in various industries, including pharmaceuticals, agrochemicals, and fine chemicals. The chiral synthesis technology platform encompasses a range of techniques such as asymmetric synthesis, biocatalysis, and resolution methods. Asymmetric synthesis involves the introduction of a chiral catalyst or reagent during the chemical reaction to selectively form one enantiomer over the other. Biocatalysis exploits the use of enzymes or microorganisms to perform chiral transformations, often with high selectivity and efficiency. Resolution methods involve the separation of enantiomers through physical or chemical means. The platform may also include advanced analytical techniques for chiral analysis and characterization, such as chiral chromatography, chiroptical spectroscopy, and computational methods for predicting and optimizing chiral synthesis processes. By utilizing the chiral synthesis technology platform, researchers and industry professionals can access a versatile toolkit for the synthesis, separation, and analysis of chiral molecules. This platform enables the development of enantiomerically pure compounds, which are crucial for the production of safe and effective drugs, agrochemicals with improved selectivity, and fine chemicals with desirable properties.
For a complete breakdown of market segmentation, vendor landscapes, and regional forecasts, industry stakeholders can access the original dataset.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5985577/chiral-synthesis-technology-platform
Market Segmentation by Deployment and Application
The chiral synthesis technology platform market is segmented as below to reflect distinct operational models and end-user requirements:
Selected Key Players (Partial List):
ChiRial, ABA CHEMICALS CORPORATION, Solvias, BOCSCI, Enantia, Aurisco, SUNNOVO, LANGHUA, ASTATECH, HEZE PHARMACEUTICAL, CHENGDU LIKAI CHIRAL TECH CO., LTD., Further Pharma, JIUZHOU Pharmaceutical, Haoyuan Chemexpress, Hanhong Group, WuXi AppTec
Segment by Deployment Type
- Cloud Based (in silico chiral prediction, AI-assisted route design)
- On Premises (in-house asymmetric synthesis workflows)
Segment by Application
- Medical (single-enantiomer APIs)
- Bio-pharmaceuticals (peptides, oligonucleotides)
- Chemical (specialty intermediates)
- Agricultural (chiral pesticides, herbicides)
- Others (flavors, fragrances, electronic chemicals)
Technical Deep Dive: Biocatalysis vs. Asymmetric Synthesis in Pharmaceutical Manufacturing
Unlike traditional resolution methods which inherently waste 50% of the undesired enantiomer, modern chiral synthesis technology platform solutions focus on stereoselective construction. Recently, biocatalysis has gained significant traction, particularly for complex molecules where metal-catalyzed asymmetric synthesis faces challenges such as heavy metal residue and low turnover numbers. In Q1 2025, WuXi AppTec reported a 40% reduction in manufacturing costs for a key intermediate of a GLP-1 analogue by switching from a ruthenium-based asymmetric hydrogenation to an engineered transaminase biocatalytic route. This real-world case underscores why contract research organizations (CROs) and CDMOs are aggressively investing in enzyme engineering capabilities.
A critical distinction exists between discrete manufacturing (typical in pharmaceutical batch processing) and flow chemistry (increasingly adopted for chiral intermediates). While batch processes rely on optimized asymmetric synthesis cycles, continuous flow platforms enable real-time monitoring of enantiomeric excess (ee) using inline chiral HPLC, reducing out-of-specification risks. For example, Solvias, in collaboration with a European generic drug manufacturer, implemented a continuous biocatalytic reduction process for a chiral alcohol intermediate in December 2025, achieving >99.5% ee at a production scale of 200 kg/day.
Regulatory Drivers and Policy Milestones
The FDA’s 2024 guidance on “Development of New Stereoisomeric Drugs” and the ICH Q13 guideline on continuous manufacturing have directly accelerated adoption of chiral synthesis technology platforms. In September 2025, the European Medicines Agency (EMA) published a reflection paper on the use of biocatalysis in pharmaceutical development, recognizing it as a preferred technology for environmentally sustainable chiral synthesis. Meanwhile, China’s NMPA has included chiral purity testing in its 2025 pharmacopoeia revision, compelling domestic API manufacturers to upgrade from classical resolution to modern asymmetric synthesis or biocatalysis routes.
Industry Sub-segment Divergence: Pharmaceuticals vs. Agrochemicals
In the pharmaceutical segment, which accounted for 68% of the chiral synthesis technology platform market in 2025, demand is concentrated on late-stage clinical and commercial enantiopure APIs. Conversely, the agrochemical segment is experiencing a shift toward chiral pesticides with single-enantiomer formulations, driven by the EU’s “Green Deal” requirement to reduce ecotoxicity. For example, the fungicide metalaxyl is gradually being replaced by metalaxyl-M, which requires efficient biocatalysis-based resolution. This has created a niche but fast-growing revenue stream for Chinese platforms such as CHENGDU LIKAI CHIRAL TECH and ASTATECH.
Future Outlook and Strategic Recommendations
As the chiral synthesis technology platform evolves, companies should prioritize hybrid workflows combining AI-driven retrosynthesis (for route scouting) with enzyme screening platforms (for biocatalysis optimization). The shift from “chiral separation” to “chiral construction” will define competitive advantages. Investments in cloud-based chiral prediction tools are expected to yield 20–30% reductions in development time for novel chemical entities (NCEs) by 2028. For drug developers, partnering with platforms that offer both asymmetric synthesis and biocatalysis from milligram to kilogram scale will be the key to de-risking regulatory submissions and achieving speed-to-market.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
